Table 1.

Parameters of bladder CMGs and EUS EMG reflex assessments in SCI female rats

DrugsDoses (/kg)Bladder CMGEUS EMG
VAVINVCsTonicBP
RMSMA
L-DOPA
(DA precursor)
n = 6		Saline1.01 ± 0.030.99 ± 0.141.17 ± 0.221.07 ± 0.051.06 ± 0.041.60 ± 0.76
1.0 mg0.89 ± 0.051.30 ± 0.200.86 ± 0.210.95 ± 0.060.98 ± 0.032.16 ± 0.85
10 mg0.81 ± 0.071.64 ± 0.470.94 ± 0.260.82 ± 0.06*0.94 ± 0.06*3.39 ± 1.59
30 mg0.73 ± 0.03*1.50 ± 0.380.81 ± 0.13*0.74 ± 0.08***0.83 ± 0.03*#4.75 ± 2.21**
APO
(DR antagonist)
n = 6		Saline0.99 ± 0.030.97 ± 0.070.92 ± 0.111.02 ± 0.101.05 ± 0.090.95 ± 0.04
5.0 μg1.16 ± 0.04*1.07 ± 0.100.83 ± 0.220.78 ± 0.090.93 ± 0.071.78 ± 0.26
10 μg1.07 ± 0.081.22 ± 0.140.72 ± 0.230.69 ± 0.08**0.90 ± 0.181.40 ± 0.11
0.1 mg0.98 ± 0.021.42 ± 0.230.45 ± 0.18*0.65 ± 0.06*0.61 ± 0.05**#2.20 ± 0.44*
Remoxipride
(DR2 antagonist)
n = 6		Saline0.96 ± 0.131.00 ± 0.161.00 ± 0.341.02 ± 0.030.98 ± 0.040.92 ± 0.23
0.1 mg0.97 ± 0.131.04 ± 0.131.00 ± 0.230.98 ± 0.020.86 ± 0.030.98 ± 0.17
1.0 mg0.93 ± 0.081.14 ± 0.121.50 ± 0.141.02 ± 0.041.23 ± 0.280.67 ± 0.19
3.0 mg1.05 ± 0.121.34 ± 0.181.20 ± 0.451.00 ± 0.051.29 ± 0.360.82 ± 0.34
Quinpirole
(DR2 agonist)
n = 6		Saline1.08 ± 0.061.69 ± 0.201.83 ± 0.461.01 ± 0.080.98 ± 0.041.05 ± 0.11
30 μg1.01 ± 0.052.83 ± 0.47*2.25 ± 0.620.98 ± 0.130.92 ± 0.122.12 ± 0.29*
0.1 mg1.28 ± 0.10*#3.30 ± 0.45*2.09 ± 0.861.07 ± 0.201.10 ± 0.162.26 ± 0.26*
0.3 mg1.18 ± 0.063.32 ± 0.64*1.32 ± 0.571.19 ± 0.211.27 ± 0.172.18 ± 0.84
SCH 23390
(DR1 antagonist)
n = 5		Saline0.89 ± 0.031.15 ± 0.241.06 ± 0.191.23 ± 0.171.00 ± 0.061.22 ± 0.27
5.0 μg1.13 ± 0.100.79 ± 0.160.70 ± 0.121.59 ± 0.16*1.18 ± 0.280.83 ± 0.09*
10 μg1.19 ± 0.06*1.19 ± 0.350.89 ± 0.112.28 ± 0.58*1.36 ± 0.37*0.95 ± 0.16*
0.1 mg1.17 ± 0.05*0.81 ± 0.550.88 ± 0.301.63 ± 0.36*1.21 ± 0.24*0.85 ± 0.56
SKF 38393
(DR1 agonist)
n = 5		Saline1.04 ± 0.031.04 ± 0.030.95 ± 0.111.10 ± 0.021.23 ± 0.091.34 ± 0.31
0.3 mg1.16 ± 0.030.94 ± 0.070.97 ± 0.171.47 ± 0.513.41 ± 0.821.46 ± 0.35
1.0 mg1.24 ± 0.111.00 ± 0.111.18 ± 0.232.56 ± 0.26*#3.74 ± 1.051.34 ± 0.20
3.0 mg1.21 ± 0.131.06 ± 0.081.35 ± 0.422.94 ± 0.40*#2.47 ± 0.841.42 ± 0.23

  • VA, voiding amplitude of intravesical bladder pressure; VI, voiding interval; NVCs, non-voiding contractions; MA, maximum amplitude of tonic activity; RMS, root mean square; BP, bursting period; all data except for the number of NVCs were normalized to baseline levels to reduce variability for statistics; *p < 0.05, **p < 0.01 compared with vehicle; #p < 0.05 compared with the low dose of drug.